Repeated injection of pegylated liposomal antitumour drugs induces the disappearance of the rapid distribution phase

Journal of Pharmacy and Pharmacology

Volumn 60, Issue 12, 2008, Pages 1651-1657

  Cui, JingXia ^a   Li, ChunLei ^b   Wang, CaiXia ^b   Li, YanHui ^b   Zhang, Lan ^b   Zhang, Li ^b   Yang, HaiYan ^a  

^a HEBEI MEDICAL UNIVERSITY   (China)

^b Zhongqi Pharmaceutical Technology Shijiazhuang Co Ltd   (China)

Author keywords

[No Author keywords available]

Indexed keywords

DOXORUBICIN; MACROGOL 2000; MITOXANTRONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; COMPARTMENT MODEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG DISTRIBUTION; DRUG LIVER LEVEL; DRUG UPTAKE; LIPOSOMAL DELIVERY; MOUSE; NONHUMAN; PARTICLE SIZE; SPLEEN; TISSUE DISTRIBUTION; ZETA POTENTIAL;

EID: 56849126358     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/jpp.60.12.0011     Document Type: Article

References (34)

1. Ahmad, A., Wang, Y. F., Ahmad, I. (2005) Separation of liposome-entrapped mitoxantrone from nonliposomal mitoxantrone in plasma: pharmacokinetics in mice. Methods Enzymol. 391: 176-185
2. Allen, T. M. (1994) Long-circulating (sterically stabilized) liposomes for targeted drug delivery. Trends Pharmacol. Sci. 15: 215-220
3. Allen, T. M. (1998) Liposomal drug formulations. Rationale for development and what we can expect for the future. Drugs 56: 747-756
4. Cattel, L., Ceruti, M., Dosio, F. (2003) From conventional to stealth liposomes: a new frontier in cancer chemotherapy. Tumori 89: 237-249
5. Coukell, A. J., Spencer, C. M. (1997) Polyethylene glycol-liposomal doxorubicin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in the management of AIDS-related Kaposi's sarcoma. Drugs 53: 520-538
6. Cui, J., Li, C., Guo, W., Li, Y., Wang, C., Zhang, L., Zhang, L., Hao, Y., Wang, Y. (2007) Direct comparison of two pegylated liposomal doxorubicin formulations: is AUC predictive for toxicity and efficacy? J. Control. Release 118: 204-215
7. Drummond, D. C., Meyer, O., Hong, K., Kirpotin, D. B., Papahadjopoulos, D. (1999) Optimizing liposomes for delivery of chemotherapeutic agents to solid tumors. Pharmacol. Rev. 51: 691-743
8. Fox, E. J. (2004) Mechanism of action of mitoxantrone. Neurology 63: S15-S18
9. Gabizon, A. A. (1994) Liposomal anthracyclines. Hematol. Oncol. Clin. North Am. 8: 431-450
10. Gabizon, A., Martin, F. (1997) Polyethylene glycol-coated (pegylated) liposomal doxorubicin. Rationale for use in solid tumours. Drugs 54 (Suppl. 4): 15-21
11. Gabizon, A., Shmeeda, H., Barenholz, Y. (2003) Pharmacokinetics of pegylated liposomal doxorubicin: review of animal and human studies. Clin. Pharmacokinet. 42: 419-436
12. Immordino, M. L., Dosio, F., Cattel, L. (2006) Stealth liposomes: review of the basic science, rationale, and clinical applications, existing and potential. Int. J. Nanomedicine 1: 297-315
13. Ishida, T., Kiwada, H. (2008) Accelerated blood clearance (ABC) phenomenon upon repeated injection of PEGylated liposomes. Int. J. Pharm. 354: 56-62
14. Ishida, T., Maeda, R., Ichihara, M., Mukai, Y., Motoki, Y., Manabe, Y., Irimura, K., Kiwada, H. (2002) The accelerated clearance on repeated injection of pegylated liposomes in rats: laboratory and histopathological study. Cell Mol. Biol. Lett. 7: 286
15. Ishida, T., Maeda, R., Ichihara, M., Irimura, K., Kiwada, H. (2003a) Accelerated clearance of PEGylated liposomes in rats after repeated injections. J. Control. Release 88: 35-42
16. Ishida, T., Masuda, K., Ichikawa, T., Ichihara, M., Irimura, K., Kiwada, H. (2003b) Accelerated clearance of a second injection of PEGylated liposomes in mice. Int. J. Pharm. 255: 167-174
17. Ishida, T., Ichikawa, T., Ichihara, M., Sadzuka, Y., Kiwada, H. (2004) Effect of the physicochemical properties of initially injected liposomes on the clearance of subsequently injected PEGylated liposomes in mice. J. Control. Release 95: 403-412
18. Ishida, T., Harada, M., Wang, X. Y., Ichihara, M., Irimura, K., Kiwada, H. (2005) Accelerated blood clearance of PEGylated liposomes following preceding liposome injection: effects of lipid dose and PEG surface-density and chain length of the first-dose liposomes. J. Control. Release 105: 305-317
19. Ishida, T., Ichihara, M., Wang, X., Kiwada, H. (2006a) Spleen plays an important role in the induction of accelerated blood clearance of PEGylated liposomes. J. Control. Release 115: 243-250
20. Ishida, T., Atobe, K., Wang, X., Kiwada, H. (2006b) Accelerated blood clearance of PEGylated liposomes upon repeated injections: effect of doxorubicin-encapsulation and high-dose first injection. J. Control. Release 115: 251-258
21. Ishida, T., Ichihara, M., Wang, X., Yamamoto, K., Kimura, J., Majima, E., Kiwada, H. (2006c) Injection of PEGylated liposomes in rats elicits PEG-specific IgM, which is responsible for rapid elimination of a second dose of PEGylated liposomes. J. Control. Release 112: 15-25
22. Ishida, T., Wang, X., Shimizu, T., Nawata, K., Kiwada, H. (2007) PEGylated liposomes elicit an anti-PEG IgM response in a T cell-independent manner. J. Control. Release 122: 349-355
23. Ishida, T., Kashima, S., Kiwada, H. (2008) The contribution of phagocytic activity of liver macrophages to the accelerated blood clearance (ABC) phenomenon of PEGylated liposomes in rats. J. Control. Release 126: 162-165
24. Lasic, D. D., Ceh, B., Stuart, M. C., Guo, L., Frederik, P. M., Barenholz, Y. (1995) Transmembrane gradient driven phase transitions within vesicles: lessons for drug delivery. Biochim. Biophys. Acta 1239: 145-156
25. Medina, O. P., Zhu, Y., Kairemo, K. (2004) Targeted liposomal drug delivery in cancer. Curr. Pharm. Des. 10: 2981-2989
26. Moghimi, S. M., Szebeni, J. (2003) Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties. Prog. Lipid Res. 42: 463-478
27. Moghimi, S. M., Hunter, A. C., Murray, J. C. (2001) Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53: 283-318
28. Oku, N., Namba, Y. (1994) Long-circulating liposomes. Crit. Rev. Ther. Drug Carrier Syst. 11: 231-270
29. Orditura, M., Quaglia, F., Morgillo, F., Martinelli, E., Lieto, E., De Rosa, G., Comunale, D., Diadema, M. R., Ciardiello, F., Catalano, G., De Vita, F. (2004) Pegylated liposomal doxorubicin: pharmacologic and clinical evidence of potent anti-tumor activity with reduced anthracycline-induced cardiotoxicity (review). Oncol. Rep. 12: 549-556
30. Reddy, K. R. (2000) Controlled-release, pegylation, liposomal formulations: new mechanisms in the delivery of injectable drugs. Ann. Pharmacother. 34: 915-923
31. Soloman, R., Gabizon, A. A. (2008) Clinical pharmacology of liposomal anthracyclines: focus on pegylated liposomal doxorubicin. Clin. Lymphoma Myeloma 8: 21-32
32. Vail, D. M., Amantea, M. A., Colbern, G. T., Martin, F. J., Hilger, R. A., Working, P. K. (2004) Pegylated liposomal doxorubicin: proof of principle using preclinical animal models and pharmacokinetic studies. Semin. Oncol. 31: 16-35
33. Wang, X. Y., Ishida, T., Ichihara, M., Kiwada, H. (2005) Influence of the physicochemical properties of liposomes on the accelerated blood clearance phenomenon in rats. J. Control. Release 104: 91-102
34. Wang, X. Y., Ishida, T., Kiwada, H. (2007) Anti-PEG IgM elicited by injection of liposomes is involved in the enhanced blood clearance of a subsequent dose of PEGylated liposomes. J. Control. Release 119: 236-244